Related Experiment Video
Updated: May 21, 2026
08:34
Inducing Myointimal Hyperplasia Versus Atherosclerosis in Mice: An Introduction of Two Valid Models
Published on: May 14, 2014
Inulin may inhibit ADAM17 to delay atherosclerosis
Wang Lijuan1,2, Du Jing1, Liang Xuegang3
1Department of Endocrinology, Ningxia Hui Autonomous Region People's Hospital, Ningxia Medical University, Yinchuan City, Ningxia, China.
Open Medicine (Warsaw, Poland)
|May 20, 2026
Summary
Inulin effectively reduces atherosclerosis by inhibiting ADAM17, a key inflammatory mediator. This study reveals inulin
Area of Science:
- Cardiovascular Research
- Inflammation Biology
- Nutraceutical Science
Background:
- Atherosclerosis is a chronic inflammatory disease.
- ADAM17 (a disintegrin and metalloproteinase domain-17) plays a crucial role in inflammatory processes.
- Inulin, a prebiotic fiber, has shown potential in modulating inflammatory conditions.
Purpose of the Study:
- To investigate the mechanism by which inulin delays atherogenesis.
- To determine if inulin mitigates inflammation by inhibiting ADAM17.
- To explore the relationship between inulin, ADAM17, and inflammatory markers in patients.
Main Methods:
- Recruited 180 patients stratified into healthy, plaque-free dyslipidemia, and atherosclerotic groups.
- Analyzed serum ADAM17 levels, inflammatory markers, and lipid profiles.
- Conducted in vitro experiments to validate inulin's effect on ADAM17-mediated inflammation.
Main Results:
- Serum ADAM17 levels increased progressively with atherosclerosis severity.
- Inulin administration significantly counteracted ADAM17-induced IL-1β upregulation.
- Inulin suppressed IL-6-induced ADAM17 expression, indicating an antagonistic relationship.
Conclusions:
- Inulin attenuates atherosclerosis by suppressing ADAM17 expression and its downstream inflammatory cascade.
- Inulin offers a novel therapeutic strategy for managing atherosclerosis through inflammation suppression.
- Targeting ADAM17 with inulin presents a promising approach to improve patient prognosis in cardiovascular disease.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:38Inflammation
Overview
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...